Last reviewed · How we verify

NCT06281015: IATOS

Artificial Intelligence and Bone Tomoscintigraphies Achieved With CZT Camera

Completed Last updated 28 February 2024
What this trial tests

trial testing Whole-body bone single photon emission tomography (SPECT) for detection or follow-up of bone metastasis in Bone Lesion in 19 participants. Completed in 30 October 2023.

Timeline
30 August 2023
Primary endpoint
10 September 2023
30 October 2023

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusCompleted
Study typeOBSERVATIONAL
Enrollment19
Start date30 August 2023
Primary completion10 September 2023
Estimated completion30 October 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

Adults 18 to 95, any sex, with Bone Lesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to determine whether the whole-body bone Single Photon Emission Computed Tomography (SPECT) recording times of around 10 minutes, routinely provided by a high-sensitivity 360 degrees cadmium and zinc telluride (CZT) camera, can be further reduced by a deep learning noise reduction (DLNR) algorithm.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bone Lesion

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06281015.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing